乙型肝炎病毒(HBV)是最易感染人类的病毒之一,统计表明全世界大约有20亿人曾受到HBV感染,其中有3.5~4亿人呈慢性感染状态,每年约有100万人死于HBV导致的肝硬化、肝功能衰竭与原发性肝癌[1]。在抗HBV治疗药物中,非环核苷膦酸酯类药物占有重要地位,这类化合物结构中具有膦酸部分, Hepatitis B virus (HBV) is one of the most susceptible to human viruses and statistics show that about 2 billion people worldwide have been infected with HBV, of which 3.5 to 400 million are chronically infected and about 1 million die each year In HBV-induced cirrhosis, liver failure and primary liver cancer [1]. In the anti-HBV drugs, non-cyclic nucleoside phosphonates occupy an important position, these compounds have a phosphonic acid moiety structure,